Novel coronavirus (COVID-19) update: Minnesota Oncology is working to protect our patients and to help prevent the spread of novel coronavirus (COVID-19). Please review our updated policies, procedures, and information here. Read Advisory

Myelodysplastic Syndromes Treatment Options

De Novo and Secondary Myelodysplastic Syndromes

Treatment of de novo and secondary myelodysplastic syndromes may include the following:

  • Supportive care with transfusion therapy
  • High-dose chemotherapy with stem cell transplant using stem cells from a donor
  • Supportive care with growth factor therapy
  • Chemotherapy with azacitidine, decitabine, or other anticancer drugs
  • Supportive care with drug therapy
  • A clinical trial of a new anticancer drug
  • A clinical trial of low-dose chemotherapy with stem cell transplant using stem cells from a donor
  • A clinical trial of a combination of treatments
  • A clinical trial of growth factor therapy

Previously Treated Myelodysplastic Syndromes

Treatment of previously treated myelodysplastic syndromes may include the following:

  • High-dose chemotherapy with stem cell transplant using stem cells from a donor
  • Chemotherapy with azacitidine or decitabine
  • Supportive care with transfusion therapy, growth factor therapy, and/or drug therapy
  • A clinical trial of low-dose chemotherapy with stem cell transplant using stem cells from a donor
  • A clinical trial of new drug therapy
  • A clinical trial of a combination of treatments
  • A clinical trial of growth factor therapy